Cover Image
市場調查報告書

前列腺癌:開發中產品分析

Prostate Cancer - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232770
出版日期 內容資訊 英文 1878 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌:開發中產品分析 Prostate Cancer - Pipeline Review, H2 2017
出版日期: 2017年12月21日 內容資訊: 英文 1878 Pages
簡介

前列腺癌是由於前列腺發病的癌症之一,男性,尤其是高齡的男性患病。主要的症狀有排尿時麻煩和力量低,血尿,腰、臀部、大腿部等的疼痛等。易罹病素質中包含年齡和家族病史,肥胖症等。主要的治療方法有外科手術和化療,放射治療等。

本報告提供全球各國的前列腺癌治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

前列腺癌概要

治療藥的開發

前列腺癌:企業開發中的治療藥

前列腺癌:大學/機關研究中的治療藥

前列腺癌:開發中產品概況

前列腺癌:企業開發中的產品

前列腺癌:大學/機關研究中的產品

前列腺癌的治療藥開發作的企業

前列腺癌:治療藥的評估

藥物簡介

前列腺癌:暫停中的計劃

前列腺癌:開發中止的產品

前列腺癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10024IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H2 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 99, 108, 5, 251, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 16, 59 and 21 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Prostate Cancer - Overview
  • Prostate Cancer - Therapeutics Development
  • Prostate Cancer - Therapeutics Assessment
  • Prostate Cancer - Companies Involved in Therapeutics Development
  • Prostate Cancer - Drug Profiles
  • Prostate Cancer - Dormant Projects
  • Prostate Cancer - Discontinued Products
  • Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Prostate Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..15), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..16), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..17), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..18), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..15), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..16), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..17), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..18), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..19), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..20), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..21), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..22), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..23), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..24), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..25), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..26), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..27), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..28), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..10), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..11), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..12), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..13), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017

List of Figures

  • Number of Products under Development for Prostate Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top